
Form Bio
Biotech · AI · Genetic Medicine
Astromech buys fellow Colossal spinoff Form Bio for $230M in stock
November 17, 2026
Deal Value
$230M
Pairing evolutionary AI with genetic-medicine design tools lets researchers catch quality flaws earlier, cutting costly downstream purification.
- Astromech, an AI company that models biological change, acquired fellow Colossal Biosciences spinoff Form Bio in an all-stock deal valued at $230 million.
- Both companies spun out of Colossal Biosciences, the de-extinction startup co-founded by Ben Lamm and Harvard geneticist George Church; Astromech builds predictive evolutionary models while Form Bio designs and tests genetic medicines.
- Form Bio co-founder and former CEO Andrew Busey becomes Astromech's chief AI officer and head of technology, and Astromech retained Form Bio's AI, engineering and product teams.
- Astromech was valued at $3.8 billion as of August and has raised more than $60 million total, including a $20 million round led by Arch Venture Partners; Form Bio had raised over $40 million since launching in 2022.
- Form Bio's design tools already support genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences.
- Astromech plans to raise a new funding round next year, CEO Ben Lamm told Axios.
- The deal reflects a broader trend of AI and biotech firms acquiring computational-biology teams and tools to build integrated research platforms rather than buy drug pipelines.